DPC JOURNAL | Top Stories, DPC Perspectives & Latest Interviews

New, EXCLUSIVE on Early CANCER DETECTION (Listen, Watch) Jo Bhakdi and Dr. Monika E. Hagen, MD, MBA Discuss Early Detection, Better Prevention and More Effective Cures for all Disease, Starting with Cancer.

By Michael Tetreault, Editor-in-Chief

Today we sit down with the two leaders in the cancer testing, genetics and precision medicine space. Cancer is routinely a concern for Doctors and Patients and preventing, testing and catching it early is so important.

“We envision a future of medicine where all disease is prevented and detected at the earliest stage.”

Quantgene unlocks the Deep Human Genome by building and deploying the world’s leading Deep Genomics solution. Our mission is to save lives through early detection, better prevention and more effective cures for all disease, starting with cancer.

Resources Discussed In Today’s Interview

Quantgene started in 2015 in a small UC Berkeley Lab under the leadership of Jo Bhakdi and Dr. Monika Hagen. Our theory was that most disease can be detected far earlier than today by introducing quantitative science and a new level of precision into medical practice. Since then, our team has spent over 4 years building the industry’s best team of pioneers and developing the GRIFFIN Deep Genomics platform. GRIFFIN combines extreme precision sequencing, software and AI technologies to profile cell-free DNA (cfDNA) fragments with unprecedented depth and precision. In 2016, Quantgene launched its first clinical feasibility trial which continues today with the goal of adding 10,000 patient samples to the GRIFFIN platform by 2020.

 

 

We are determined to build a future where everyone is protected against most diseases through early detection with our innovative technology.

Jo Bhakdi in the Santa Monica office. Source; Quantgene.comMeet. Jo Bhakdi

Jo Bhakdi is the founder and CEO of Quantgene. His work in machine learning, sequencing technology, and DNA extraction procedures defines the cutting edge of genomic diagnostics, early disease detection, and precision medicine.

Prior to Quantgene, Jo founded i2X, an investment framework that composes low-risk Venture Capital portfolios across large numbers of technology startups. The i2X platform laid important foundations for advanced analytics in both financial and biotechnology applications, such as the Quantgene machine learning platform.

Bhakdi holds a Masters in Economics and Psychology from Tubingen University, one of Germany’s leading academic institutions, with a focus on financial theory and statistics. He kicked off his career at WPP and Omnicom, where he held Strategy and Executive Director positions.

Beyond his focus on technology and the future of medicine, Bhakdi is dedicated to bringing together the best and brightest and transforming them into pioneers, pushing the boundaries of health, life, and innovation for all.

Jo Bhadki and Dr. Hagen, Quantgene

Meet Dr. Monika E. Hagen, MD, MBA

Monika E. Hagen, MD, MBA is the Chief Medical Officer of Quantgene and a board certified General Surgeon, specializing in bariatric surgery. Trained in Germany, Switzerland, and the United States, she has over a decade of experience as a medical doctor, academic surgeon, teacher, medical device expert, and clinical trial specialist. She also received her MBA from the University of Wales in Cardiff, UK.

Dr. Hagen is an international thought leader and lecturer in bariatric and minimally invasive surgery, as well as surgical robotic technology and its clinical applications. She is a frequent speaker at medical conferences and has published extensively on topics ranging from robotic surgery, to clinical trial design to the future of medicine.

Prior to joining Quantgene and utilizing her clinical, strategic planning, and business development expertise, she has served as a regular consultant to financial, technology, medical, and biotech companies. Dr. Hagen divides her time between professional roles in Geneva, Switzerland, Silicon Valley, and Santa Monica, California.

Resources Discussed In Today’s Interview

For more information, please visit: https://www.quantgene.com/ .

Contact Information:
Rachel Strohmeyer and Jo Bhakdi, CEO – jb@quantgene.com
Quantgene
951-775-0607
rachel@quantgene.com

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: